Managing Daily Life: A Team Approach to NIID Care
At a Glance
NIID has no current disease-modifying cure, so care focuses on treating symptoms and preventing complications. Neurologists and other specialists may support movement, bladder and blood pressure problems, cognition, seizures, swallowing, nutrition, safety, and independence.
Managing Neuronal Intranuclear Inclusion Disease (NIID) requires a multidisciplinary approach, meaning a team of different specialists works together to address the wide variety of symptoms that can occur [1].
Because there is currently no disease-modifying cure that stops the underlying genetic process, care focuses on supportive management: treating the symptoms you have, preventing complications, and maximizing your comfort and independence [2][1].
Managing Movement and Physical Symptoms
Movement issues in NIID, such as tremors or stiffness (parkinsonism), are often treated similarly to Parkinson’s disease, but the results can vary [3].
- Levodopa Trials: Doctors may recommend a trial of levodopa (a standard Parkinson’s medication). While some patients see improvement in their movement, others find the benefit is only temporary or limited by side effects like nausea, vomiting, orthostatic hypotension, or dyskinesia [1][4].
- Rehabilitation: Physical and Occupational Therapy are essential for maintaining mobility. Therapists focus on balance training, gait safety, and recommending assistive devices (like canes or walkers) to prevent falls, which are a significant risk in NIID [1][5].
- Weakness and Neuropathy: Since many patients have peripheral neuropathy (nerve damage), regular foot checks and comfortable, supportive footwear are important to prevent injury [6].
Addressing Autonomic and Internal Symptoms
The autonomic nervous system—which controls “automatic” functions like digestion and blood pressure—is affected in over 90% of people with NIID [7].
- Bladder Care: Bladder dysfunction is extremely common. Management may include medications to reduce urgency or, in some cases, the use of a catheter if the bladder is not emptying fully. These treatments require careful review of heart, kidney, blood-pressure, and infection risks [8][9].
- Digestive Support: Symptoms like chronic constipation or sudden bouts of vomiting require a tailored plan. For severe, drug-refractory vomiting, some patients have seen improvement with corticosteroid therapy; however, this is not a routine disease-modifying treatment and is considered by specialists only after excluding infections and weighing serious risks like high blood sugar and cognitive effects [10][11].
- Blood Pressure: Orthostatic hypotension (a drop in blood pressure when standing) can cause dizziness or fainting. Management often includes staying well-hydrated, wearing compression stockings, and carefully reviewing any medications that might lower blood pressure further, though these interventions require review of heart, kidney, and infection risks [12][10].
Cognitive, Seizure, and Safety Monitoring
As the disease progresses, cognitive changes and sudden neurological “episodes” need proactive management.
- Cognitive Support: While medications like donepezil are sometimes used for memory, their effectiveness in NIID is not yet proven [5]. Care focuses on environmental safety, cognitive exercises, and treating secondary issues like anxiety or depression [13].
- Seizure Management: Sudden episodes of confusion or “stroke-like” events may actually be seizures [14]. If an EEG (a test of brain waves) shows seizure activity, doctors will prescribe anti-seizure medications (ASMs) to help stabilize brain activity [15].
- Swallowing and Nutrition: NIID can cause dysphagia (difficulty swallowing), which increases the risk of aspiration (food or liquid entering the lungs) [16]. A speech-language pathologist can perform a swallowing study to recommend safe food textures and techniques [16].
The Importance of a Care Team
Because NIID is complex, your team should ideally include a neurologist, urologist, gastroenterologist, and physical therapist [1]. Early involvement of a palliative care specialist can also be helpful—not just for end-of-life care, but to help manage complex symptoms and improve your daily quality of life at any stage of the journey [1].
Common questions in this guide
Is there a treatment that stops NIID from progressing?
What can help movement problems in NIID?
How are bladder and blood pressure symptoms treated in NIID?
How can doctors check whether the bladder is emptying fully?
What should I do if NIID makes swallowing difficult?
Could sudden confusion or a stroke-like episode be a seizure in NIID?
Which specialists are usually involved in NIID care?
Get notified when new evidence is published on Neuronal intranuclear inclusion disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
Levodopa intolerance as a potential clinical red flag for neuronal intranuclear inclusion disease (NIID) in atypical parkinsonism: a case report.
Zang P, Liu Y, Hao Y
BMC neurology 2026; (26(1)).
PMID: 41634634 - 2
Neuronal intranuclear inclusion disease with subclinical peripheral neuropathy: A case report.
Sun L, Zhou L, Ren L, et al.
Medicine 2024; (103(47)):e40636 doi:10.1097/MD.0000000000040636.
PMID: 39809216 - 3
Neuronal intranuclear inclusion disease misdiagnosed as Parkinson's disease: a case report.
Yu D, Li J, Tai H, et al.
The Journal of international medical research 2024; (52(3)):3000605241233159 doi:10.1177/03000605241233159.
PMID: 38436278 - 4
Neuronal Intranuclear Inclusion Disease: Longitudinal Case Report of Motor and Nonmotor Symptoms.
Vermilion J, Johnson M, Srinivasan J, Mink JW
Journal of child neurology 2019; (34(13)):801-805 doi:10.1177/0883073819860566.
PMID: 31304825 - 5
[Adult-Onset Neuronal Intranuclear Inclusion Disease in Two Female Siblings].
Yoshimoto T, Takamatsu K, Kurashige T, et al.
Brain and nerve = Shinkei kenkyu no shinpo 2017; (69(3)):267-274 doi:10.11477/mf.1416200737.
PMID: 28270636 - 6
Diagnostic value of nerve conduction study in NOTCH2NLC-related neuronal intranuclear inclusion disease.
Tian Y, Hou X, Cao W, et al.
Journal of the peripheral nervous system : JPNS 2023; (28(4)):629-641 doi:10.1111/jns.12599.
PMID: 37749855 - 7
Characteristics of autonomic dysfunction in neuronal intranuclear inclusion disease.
Zhou L, Tian Y, Zhang S, et al.
Frontiers in neurology 2023; (14()):1168904 doi:10.3389/fneur.2023.1168904.
PMID: 37388545 - 8
Urodynamic Assessment of Neuronal Intranuclear Inclusion Disease.
Aiba Y, Sakakibara R, Lee FC, Tateno F
European neurology 2020; (83(3)):312-316 doi:10.1159/000508746.
PMID: 32645705 - 9
Adult-Onset Neuronal Intranuclear Inclusion Disease Initially Manifesting as Bladder Dysfunction: A Case Report.
Yamaki A, Sekino H, Kawana S, et al.
Cureus 2026; (18(3)):e105488 doi:10.7759/cureus.105488.
PMID: 42005169 - 10
Rapidly progressive adult-onset neuronal intranuclear inclusion disease beginning with autonomic symptoms: a case report.
Zhu Y, Yang Q, Tian Y, et al.
Frontiers in neurology 2023; (14()):1190981 doi:10.3389/fneur.2023.1190981.
PMID: 37305750 - 11
Adult-onset neuronal intranuclear inclusion disease initially presenting with prominent gastrointestinal symptoms: a case report.
Yuan X, Yang Y, Tang Y, Luo Q
BMC neurology 2026; (26(1)).
PMID: 41845318 - 12
Blepharoptosis As an Early Manifestation of Neuronal Intranuclear Inclusion Disease.
Miyaue N, Ochi C, Ito YH, et al.
Internal medicine (Tokyo, Japan) 2024; (63(8)):1163-1166 doi:10.2169/internalmedicine.2384-23.
PMID: 38616117 - 13
Psychiatric-onset neuronal intranuclear inclusion disease in a psychiatry-based dementia-enriched cohort in Japan.
Miyamoto T, Mori K, Akamine S, et al.
Psychiatry and clinical neurosciences 2025; (79(9)):561-571 doi:10.1111/pcn.13854.
PMID: 40515658 - 14
Clinical features of neuronal intranuclear inclusion disease with seizures: a systematic literature review.
Zhang J, Ling L, Xiang L, et al.
Frontiers in neurology 2024; (15()):1387399 doi:10.3389/fneur.2024.1387399.
PMID: 38707999 - 15
Case Report: Distinctive features of cognitive dysfunction and amelioration by antiseizure medication in neuronal intranuclear inclusion disease.
Ohara H, Yamanaka M, Okada F, et al.
Frontiers in neuroscience 2026; (20()):1734078 doi:10.3389/fnins.2026.1734078.
PMID: 41716662 - 16
Neuronal intranuclear inclusion disease presenting with dysphagia: a report of three cases.
Aoyagi Y, Taya M, Ohashi M, Saitoh E
Neurocase 2020; (26(4)):252-257 doi:10.1080/13554794.2020.1788607.
PMID: 32619141
This page is for informational purposes only and does not constitute medical advice. Your neurologist and care team can tailor NIID treatments, monitoring, and safety plans to your symptoms.